Why the study?
Does carvedilol reduce death and cardiovascular hospitalization in patients with chronic heart failure receiving standard therapy?
Does carvedilol reduce death and cardiovascular hospitalization in patients with chronic heart failure receiving standard therapy?
Carvedilol reduces mortality and cardiovascular hospitalizations in patients with chronic heart failure already treated with digoxin, diuretics, and ACE inhibitors.
Supports adding carvedilol to standard therapy in chronic HF; confirms mortality and CV hospitalization benefits in this RCT.
Carvedilol reduces the risk or death as well as the risk of hospitalization for cardiovascular causes in patients with heart failure who are receiving treatment with digoxin, diuretics, and an angiotensin-converting-enzyme inhibitor.
No takes yet. Share an insight, caveat, or question.
Packer et al. (1996) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: